Lundbeck
FDA issues CRL for Takeda/Lundbeck’s Brintellix
March 29, 2016Manufacturing and Production, Research and Development Lundbeck, Takeda, brintellix
Takeda and Lundbeck have received a complete response letter from the US Food and Drug Administration (FDA) for the supplemental …
Lundbeck gets go-ahead for US and EU licence expansions
February 4, 2016Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine
Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …
Lundbeck sheds 1,000 jobs in £284 million restructure
August 20, 2015Manufacturing and Production, Sales and Marketing Lundbeck, generics, job losses, patents, redundancies, restructure, restructuring
Lundbeck is cutting a thousand jobs globally as part of a restructuring programme to significantly lower its cost and focus …
FDA approves Lundbeck and Otsuka’s Rexulti for depression
July 14, 2015Sales and Marketing FDA, Lundbeck, Otsuka, Rexulti, US, brexpiprazole, depression, major depressive disorder, schizophrenia
Lundbeck and Otsuka have gained a yes vote from the FDA for their jointly-marketed antidepressant, Rexulti. The US regulator approved …
Lundbeck gains new chief executive from Novo Nordisk
May 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kåre Schultz, Lundbeck, Novo Nordisk, Rebien Sorensen
Danish pharma giant Lundbeck has appointed Kåre Schultz as its new president and chief executive. Schultz (pictured) will take up …
Changing our minds about depression
February 9, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Campbell, Lamb, Lundbeck, depression, economist, mind
Alastair Campbell, former Labour spin doctor and depression patient, thinks that mental and physical health should not be seen as …
Lundbeck scraps stroke drug
December 18, 2014Research and Development, Sales and Marketing AIS, DIAS, Lundbeck, acute ischemic stroke, desmoteplase, stroke
Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …
Lundbeck’s alcohol pill given NICE approval
November 27, 2014Sales and Marketing Lundbeck, NHS, NICE, alcohol, selincro
NICE has finally approved the use of Selincro (nalmefene) in order to help people who are dependent on alcohol cut …
Mental and physical health should be treated equally
November 26, 2014Medical Communications, Research and Development, Sales and Marketing Campbell, Lundbeck, depression, kofi annan, wiinberg
The need for a new approach to depression that gives it equal importance to physical health was the focus of …
Lundbeck chief executive resigns amid scandal
November 25, 2014Medical Communications, Sales and Marketing Björklund, Lundbeck, stratified medical, ulf wiinberg
Ulf Wiinberg has resigned from his chief executive post at Denmark-based pharma giant Lundbeck following a beach of its rules …
Lundbeck sales slide as generic competition bites
November 6, 2014Sales and Marketing Ebixa, Lundbeck, Q3, Xenazine, generic, onfi, sabril
Lundbeck’s sales fell dramatically in the third quarter of 2014 as it struggles with expiring patents, although several of its …
FDA accepts new schizophrenia drug filing
September 24, 2014Sales and Marketing FDA, Lundbeck, Otsuka, brexpiprazole, depression, schizophrenia
The FDA is reviewing Otsuka and Lundbeck’s brexpiprazole for the treatment of schizophrenia and as an adjunctive therapy for the …
No silver bullet, but a growing arsenal for pharma comms
September 16, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Lundbeck, comms, eyeforpharma, mcm, selincro, tim white
Digital strategies in the pharma industry have predominately been a red herring, focussing too much on the novelty of digital …
NICE ‘yes’ for Selincro
July 10, 2014Sales and Marketing Lundbeck, NHS, NICE, alcohol, nalmefene, selincro
Lundbeck has received a lift from UK drugs pricing watchdog NICE as it has recommended the firm’s alcohol dependency pill …
Avillion hires Lundbeck chief executive
June 16, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Avillion, Lundbeck, wiinberg
UK drug development firm Avillion has appointed Lundbeck chief executive Ulf Wiinberg as the chairman of its board of directors. …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
